XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 16, 2021
Jun. 08, 2017
Aug. 01, 2021
Jan. 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Commitments and Contingencies (Details) [Line Items]            
Pay licensor         $ 45,000  
License agreement, description the Company paid Arbormentis, LLC an upfront fee of $12.7 million, consisting of a mix of cash and warrants to purchase the Company’s common stock, in addition to potential milestone payments totaling up to approximately $160 million related to pre-specified development and commercialization milestones. Arbormentis, LLC is also eligible to receive a low single digit royalty on net sales of any commercialized therapy resulting from this agreement. The license agreement is terminable by the Company but is perpetual and not terminable by the licensor absent material breach of its terms by the Company.          
lease agreement monthly rent     $ 11,000      
Lease period     5 months      
Lease expenses         111,800 $ 165,900
Lease income         4,000 $ 14,900
FFE [Member]            
Commitments and Contingencies (Details) [Line Items]            
Description of lease agreement   Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (FFE) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. On June 8, 2017 the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403.        
Licensing Agreements [Member] | Wonpung [Member]            
Commitments and Contingencies (Details) [Line Items]            
License agreement         $ 1,500,000  
Net sales rate         12.00%  
Licensing Agreements [Member] | Wonpung [Member] | Business Combination [Member]            
Commitments and Contingencies (Details) [Line Items]            
Business acquisition, description         (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of December 31, 2020, the Company has not generated any revenue related to this license agreement.  
Licensing Agreements [Member]            
Commitments and Contingencies (Details) [Line Items]            
Description of rights granted to license agreement       In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.    
Minimum [Member] | Licensing Agreements [Member]            
Commitments and Contingencies (Details) [Line Items]            
Term of licensing agreement         15 years  
Maximum [Member] | Licensing Agreements [Member]            
Commitments and Contingencies (Details) [Line Items]            
Term of licensing agreement         20 years